ANTIBODIES

Contributor Information
- Name Julian Gannon
- Institute Cancer Research UK, London Research Institute: Clare Hall Laboratories
Tool Details
- Tool name: Anti-Cdk2 [AN4.3]
- Alternate names: Cyclin-Dependent Kinase 2; Cell Division Protein Kinase 2; P33 Protein Kinase; CDKN2; CDC2-Related Protein Kinase; P33(CDK2)
- Clone: AN4.3
- Tool type: Antibodies
- Tool sub-type: Primary antibody
- Class: Monoclonal
- Conjugate: Unconjugated
- Reactivity: Human ; Mouse ; Xenopus laevis
- Host: Mouse
- Application: ELISA ; FACS ; IP ; WB
- Description: Cdk2 is a cell cycle protein closely related to Cdk1 (Cdc2) and a useful marker of proliferation. Cdk2 binds cyclins A and E and controls progression into S-phase.
- Immunogen: Human recombinant Cdk2
- Isotype: IgG2a
- Research area: Cancer; Cell biology; Genetics
- Myeloma used: Sp2/0-Ag14
- For Research Use Only
Target Details
- Target: Cyclin-dependent kinase 2 (cdk2)
- Target background: Cdk2 is a cell cycle protein closely related to Cdk1 (Cdc2) and a useful marker of proliferation. Cdk2 binds cyclins A and E and controls progression into S-phase.
Application Details
- Application: ELISA ; FACS ; IP ; WB
Handling
- Format: Liquid
- Concentration: 1 mg/ml
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15ðC to -25ðC
- Shipping conditions: Shipping at 4ðC
Related Tools
References
- • Syafrizayanti et al. 2017. Sci Rep. 7:39756. PMID: 28045055.
- • Personalised proteome analysis by means of protein microarrays made from individual patient samples.
- • Chang et al. 2016. J Formos Med Assoc. :. PMID: 27773559.
- • Immunophenotypic and genetic characteristics of diffuse large B-cell lymphoma in Taiwan.
- • Chu et al. 2016. Journal of Fn Foods. 23:614-627
- • Xu et al. 2010. Biol Pharm Bull. 33(5):743-51. PMID: 20460749.
- • Targeting the Na(+)/K(+)-ATPase alpha1 subunit of hepatoma HepG2 cell line to induce apoptosis and cell cycle arresting.
- • Ottewell et al. 2009. Mol Cancer Ther. 8(10):2821-32. PMID: 19789217.
- • Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone.